Pixium Vision has CE-marked its second-generation bionic vision system, IRIS II, and plans to commercialize it in Europe at the end of this year. It is the second device of its kind to enter the market, breaking the monopoly held by Second Sight Medical Products Inc.'s for the past five years.
IRIS II is approved for people with vision loss from outer retinal degeneration. Similar to Second Sight's Argus II, which was CE marked in 2011, IRIS II includes a camera...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?